SOLANA BEACH, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company has reached an agreement to work in partnership with Spaulding Clinical Research
SOLANA BEACH, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the first quarter ended March 31, 2017 on Monday, May
Confirmed FDA acceptability of comparative exposure pharmacokinetic (PK) study design and agreement on related CMC data package elements for Gimoti™ new drug application (NDA) Partnered with Spaulding Clinical Research to complete PK study in second half of 2017 Received FDA agreement that a
SOLANA BEACH, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the second quarter ended June 30, 2017 on Monday,
Collaborated with Spaulding Clinical Research LLC and today announced the initiation of the comparative exposure pharmacokinetic (PK) study Partnered with Rho, Inc. for the preparation of the 505(b)(2) New Drug Application (NDA) for Gimoti™ NDA submission remains on track for late 2017/early
SOLANA BEACH, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global